[go: up one dir, main page]

DE60026514D1 - Neue prolinverbindungen als mikrobizide mittel - Google Patents

Neue prolinverbindungen als mikrobizide mittel

Info

Publication number
DE60026514D1
DE60026514D1 DE60026514T DE60026514T DE60026514D1 DE 60026514 D1 DE60026514 D1 DE 60026514D1 DE 60026514 T DE60026514 T DE 60026514T DE 60026514 T DE60026514 T DE 60026514T DE 60026514 D1 DE60026514 D1 DE 60026514D1
Authority
DE
Germany
Prior art keywords
prolin
microbicide
compounds
medium
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60026514T
Other languages
English (en)
Other versions
DE60026514T2 (de
Inventor
Aaron H Leeman
Milton L Hammond
Milana Maletic
Gina M Santorelli
Sherman F Waddell
John Finn
Michael Morytko
Siya Ram
Dennis Keith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cubist Pharmaceuticals LLC
Merck and Co Inc
Original Assignee
Cubist Pharmaceuticals LLC
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cubist Pharmaceuticals LLC, Merck and Co Inc filed Critical Cubist Pharmaceuticals LLC
Application granted granted Critical
Publication of DE60026514D1 publication Critical patent/DE60026514D1/de
Publication of DE60026514T2 publication Critical patent/DE60026514T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
DE60026514T 1999-05-05 2000-05-05 Neue prolinverbindungen als mikrobizide mittel Expired - Fee Related DE60026514T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13254699P 1999-05-05 1999-05-05
US132546P 1999-05-05
PCT/US2000/012172 WO2000066119A1 (en) 1999-05-05 2000-05-05 Novel prolines as antimicrobial agents

Publications (2)

Publication Number Publication Date
DE60026514D1 true DE60026514D1 (de) 2006-05-04
DE60026514T2 DE60026514T2 (de) 2006-11-09

Family

ID=22454536

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60026514T Expired - Fee Related DE60026514T2 (de) 1999-05-05 2000-05-05 Neue prolinverbindungen als mikrobizide mittel

Country Status (9)

Country Link
US (3) US6333344B1 (de)
EP (1) EP1176959B1 (de)
JP (1) JP2002543129A (de)
AT (1) ATE319446T1 (de)
AU (1) AU769652B2 (de)
CA (1) CA2372176A1 (de)
DE (1) DE60026514T2 (de)
ES (1) ES2257296T3 (de)
WO (1) WO2000066119A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120940T2 (de) * 2000-03-27 2007-01-25 Applied Research Systems Ars Holding N.V. Pyrrolidin-derivate verwendbar als bax-inhibitoren
JP2003529584A (ja) * 2000-03-27 2003-10-07 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Ｂａｘ阻害剤としての医薬として活性なピロリジン誘導体
CN100471838C (zh) 2000-12-28 2009-03-25 第一制药株式会社 Vla-4抑制剂
IL159219A0 (en) * 2001-06-18 2004-06-01 Applied Research Systems Pyrrolidine oxadiazole derivatives, their preparation and pharmaceutical compositions containing them
ATE516802T1 (de) * 2002-04-19 2011-08-15 Univ Arizona State Verfahren zur modulierung der phototoxizität
AU2004258821A1 (en) * 2003-05-01 2005-02-03 Replidyne, Inc. Antibacterial methods and compositions
WO2005009992A1 (ja) 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. シクロヘキサンカルボン酸類
JP2006143667A (ja) * 2004-11-22 2006-06-08 Ube Ind Ltd ピペコリン酸アミド誘導体及び抗菌剤
NZ563186A (en) 2005-05-03 2011-09-30 Ranbaxy Lab Ltd Antimicrobial agents
JP2009533315A (ja) * 2006-04-10 2009-09-17 ランバクシー ラボラトリーズ リミテッド 抗菌剤
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
MX394449B (es) * 2012-01-12 2025-03-11 Univ Yale Compuestos y metodos para degradacion mejorada de proteinas y otros polipeptidos elegidos como blanco mediante una ubiquitina ligasa e3.
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
US10913736B2 (en) * 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
KR102564925B1 (ko) 2015-01-20 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CA2979070A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
EP3302482A4 (de) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-bindende kinase-1-protacs und zugehörige verfahren zur verwendung
EP3337476A4 (de) 2015-08-19 2019-09-04 Arvinas, Inc. Verbindungen und verfahren für den gezielten abbau von bromdomänenhaltigen proteinen
WO2017079267A1 (en) 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
US20180072711A1 (en) 2016-09-15 2018-03-15 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
KR20250044800A (ko) 2016-10-11 2025-04-01 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적 분해용 화합물 및 방법
EP3535265A4 (de) 2016-11-01 2020-07-08 Arvinas, Inc. Auf tau-protein abzielende protacs und zugehörige verfahren zur verwendung
PL3689868T3 (pl) 2016-12-01 2024-03-11 Arvinas Operations, Inc. Pochodne tetrahydronaftalenu i tetrahydroizochinoliny jako degradery receptorów estrogenowych
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
WO2018118598A1 (en) 2016-12-23 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
CN110753693A (zh) 2016-12-23 2020-02-04 阿尔维纳斯运营股份有限公司 Egfr蛋白水解靶向嵌合分子和相关使用方法
CN117510491A (zh) 2016-12-23 2024-02-06 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
CN110612294B (zh) 2017-01-31 2024-01-16 阿尔维纳斯运营股份有限公司 人小脑蛋白配体和包含其的双官能化合物
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
MX2020010420A (es) 2018-04-04 2020-12-11 Arvinas Operations Inc Moduladores de la proteólisis y métodos asociados de uso.
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
CN119954801A (zh) 2019-07-17 2025-05-09 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
CN119019369A (zh) 2019-10-17 2024-11-26 阿尔维纳斯运营股份有限公司 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
CN115175901B (zh) 2019-12-19 2024-03-22 阿尔维纳斯运营股份有限公司 用于雄激素受体的靶向降解的化合物和方法
EP4146642A1 (de) 2020-05-09 2023-03-15 Arvinas Operations, Inc. Verfahren zur herstellung einer bifunktionellen verbindung, ultrareine formen der bifunktionellen verbindung und dosierungsformen damit
JP2023539663A (ja) 2020-08-28 2023-09-15 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
BR112023004656A2 (pt) 2020-09-14 2023-05-09 Arvinas Operations Inc Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio
WO2022221673A1 (en) 2021-04-16 2022-10-20 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
US12496301B2 (en) 2023-12-08 2025-12-16 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
ES520132A0 (es) 1982-02-27 1984-04-01 Beecham Group Plc Un procedimiento para la preparacion de derivados de 1-normon-2-ilo.
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
JPH03236389A (ja) * 1990-02-13 1991-10-22 Banyu Pharmaceut Co Ltd ２―（２―カルバモイルピロリジニルチオ）カルバペネム誘導体
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
JPH09504512A (ja) 1993-08-13 1997-05-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 抗菌活性、抗マイコプラズマ活性、抗真菌類活性および除草活性を有するモン酸ａおよびｃの誘導体
US5705487A (en) 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
JPH10505328A (ja) * 1994-07-20 1998-05-26 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング ヘリコバクター細菌類を撲滅するためのピペラジノチオピリジン
US5726195A (en) 1995-07-28 1998-03-10 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
AU6500696A (en) 1995-07-28 1997-02-26 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
WO1997010225A1 (en) * 1995-09-15 1997-03-20 Smithkline Beecham Plc Pyrrolidine and thiazole derivatives with antibacterial and metallo-beta-lactamase inhibitory properties

Also Published As

Publication number Publication date
US6417217B1 (en) 2002-07-09
EP1176959B1 (de) 2006-03-08
DE60026514T2 (de) 2006-11-09
US6333344B1 (en) 2001-12-25
AU769652B2 (en) 2004-01-29
CA2372176A1 (en) 2000-11-09
WO2000066119A1 (en) 2000-11-09
EP1176959A4 (de) 2002-10-09
AU4984500A (en) 2000-11-17
ES2257296T3 (es) 2006-08-01
EP1176959A1 (de) 2002-02-06
US20030013724A1 (en) 2003-01-16
US6579894B2 (en) 2003-06-17
ATE319446T1 (de) 2006-03-15
JP2002543129A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
DE60026514D1 (de) Neue prolinverbindungen als mikrobizide mittel
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
LU92824I2 (fr) Ceritinib ou un sel pharmaceutiquement acceptable de celui-ci
WO2002094794A8 (en) 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
BG107195A (en) AMIDE COMPOUND AND ITS APPLICATION AS Rho KINASE INHIBITOR
ATE241617T1 (de) Pyrimidinverbindungen
DK0418845T3 (da) Pyrazolderivater, fremgangsmåder til fremstilling deraf og farmaceutisk præparat omfattende samme
YU44998A (sh) Pirazolska jedinjenja, postupci za njihovu proizvodnju i herbicidi koji ih sadrže
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
ATE259376T1 (de) Heterozyklische verbindungen, ihre zwischenprodukte und elastase-inhibitoren
MXPA03010439A (es) Derivados de 4-(fenil-piperidin-a-iliden-metil)-benzamida y su uso para tratar dolor, ansiedad o trastornos gastrointestinales.
EE05035B1 (et) 1-[fenüül-(8-kinolinüül)metüül]piperasiini derivaadid ning nende kasutamine meditsiinis
MXPA03010443A (es) Derivados de 4-(fenil-piperidin-4-iliden-metil)-benzamida y su uso para tratar dolor, ansiedad o trastornos gastrointestinales.
DE60201921D1 (de) Kondensierte Pyrazolverbindungen
CA2409842A1 (en) 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
BR0213176A (pt) Derivados microbiocidas de n-fenil-n-[4-(4-piridil)-2-pirimidin-2-il]amina
FI935798A0 (fi) Alkylsubstituerade heterocykliska foereningar
MEP17408A (en) N-(heterocyclyl)benzene or pyridine sulphonamides as antithrombotic agents and anticoagulants
BG106784A (en) 3-(4,5-dihydroisoxalole-5-yl)benzoylpyrazole
CA2170637A1 (en) Pyridazinone derivatives or their salts, processes for their production, and anti-shock agents containing them
MXPA03010442A (es) Derivados de 4-(fenil-(piperidin-4-il)-amino)-benzamida y sus usos para tratamiento de dolor, ansiedad o desordenes gastrointestinales.
GB0003257D0 (en) Heterocyclic compounds and their therapeutic use
EP0721930A4 (de) Benzoethylenderivat
SE0101769D0 (sv) Novel compounds
MXPA03010438A (es) Derivados de 4-(fenil-piperidin-4-iliden-metil)-benzamida y su uso para tratar dolor, ansiedad o transtornos gastrointestinales.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO, INC., RAHWAY, N.J., US

Owner name: CUBIST PHARMACEUTICALS, INC., LEXINGTON, MASS., US

8339 Ceased/non-payment of the annual fee